Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated Phase 4 Interventional Results available

Prophylactic Phenobarbital After Neonatal Seizures

NCT01089504
Conditions
Neonatal Seizures
Interventions
phenobarbital, placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
2 Days to 2 Weeks
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
18
States / cities
Little Rock, Arkansas • San Francisco, California • Iowa City, Iowa + 12 more
Conditions
Neonatal Seizures
Interventions
Surveys, EEG
Other
Lead sponsor
University of Michigan
Other
Eligibility
0 Weeks to 24 Months
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
San Francisco, California • Stanford, California • Washington D.C., District of Columbia + 5 more
Completed Phase 1Phase 2 Interventional Results available

Efficacy of Intravenous Levetiracetam in Neonatal Seizures

NCT01720667
Conditions
Neonatal Seizures
Interventions
Intravenous levetiracetam, Intravenous phenobarbital
Drug
Lead sponsor
Richard H. Haas
Other
Eligibility
15 Minutes to 14 Days
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Diego, California
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Conditions
Epilepsy
Interventions
perampanel
Drug
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions
RAD001, Placebo, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temodar, O6-BG, and Irinotecan
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Neonatal Abstinence Syndrome
Interventions
Phenobarbital, Clonidine
Drug
Lead sponsor
University of Tennessee Medical Center
Other
Eligibility
35 Weeks and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Knoxville, Tennessee
Completed Phase 3 Interventional Results available

Improving Outcomes in Neonatal Abstinence Syndrome

NCT01958476
Conditions
Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal
Interventions
Neonatal Morphine Solution, Methadone, Phenobarbital
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
Not listed
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
8
States / cities
Jacksonville, Florida • Portland, Maine • Boston, Massachusetts + 4 more
Completed Not applicable Interventional Results available

Phenobarbital for Acute Alcohol Withdrawal

NCT01184417
Conditions
Alcohol Withdrawal
Interventions
10 mg/kg IV phenobarbital in 100 ml saline, placebo
Drug
Lead sponsor
Jonathan Rosenson
Other
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oakland, California
Terminated Not applicable Interventional Results available

Clonidine for Neonatal Abstinence Syndrome Study

NCT01175668
Conditions
Neonatal Abstinence Syndrome
Interventions
Clonidine, Phenobarbital
Drug
Lead sponsor
Baystate Medical Center
Other
Eligibility
Up to 15 Days
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Springfield, Massachusetts
Conditions
Clopidogrel Resistance, Secondary Stroke Prevention
Interventions
Primidone
Drug
Lead sponsor
Dent Neuroscience Research Center
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Amherst, New York
Completed Phase 4 Interventional Results available

Treatment of Neonatal Abstinence Syndrome

NCT01723722
Conditions
Neonatal Abstinence Syndrome
Interventions
Methadone, Diluted Deodorized Tincture of Opium
Drug
Lead sponsor
Eastern Maine Medical Center
Other
Eligibility
1 Day to 6 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bangor, Maine
Conditions
Epilepsy
Interventions
Phenobarbital, Placebo
Drug · Other
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Toledo, Ohio
Conditions
Neonatal Seizure, Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy, Seizure Newborn
Interventions
Levetiracetam Injection, Phenobarbital Sodium Injection
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 1 Month
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
San Diego, California • Minneapolis, Minnesota
Conditions
Neonatal Seizures
Interventions
levetiracetam
Drug
Lead sponsor
Stephanie Merhar, MD
Other
Eligibility
Up to 30 Days
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Seizures, Encephalopathy
Interventions
EEG monitoring and treatment of EEG seizures
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Hour to 72 Hours
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioma
Interventions
enzyme-inducing anti-epileptic drugs
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
Interventions
Oral Topotecan and Temodar
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Blood Cancer, Leukemia, Graft Versus Host Disease, Malignancy, CLL, NHL, Hodgkin's Disease, MDS
Interventions
non-myeloablative hematopoietic cell transplantation, Anti-Thymocyte Globulin, Cyclosporine, Mycophenolate Mofetil, G-CSF, Solumedrol, Acetaminophen, Diphenydramine, Hydrocortisone
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
12 Months and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Stanford, California
Conditions
Gliosarcoma, Glioblastoma, Anaplastic Astrocytoma
Interventions
Temodar and SCH 66336
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Brain and Central Nervous System Tumors
Interventions
terameprocol, pharmacological study
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Conditions
Seizures
Interventions
Bumetanide, Normal Saline as Placebo
Drug
Lead sponsor
Soul, Janet , M.D.
Individual
Eligibility
Up to 44 Weeks
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts
Conditions
Brain and Central Nervous System Tumors
Interventions
radiation therapy, Celecoxib
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 4 more